EUCTR2010-022991-29-GB进行中（未招募）不适用
A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid-induced Bowel Dysfunction
Sucampo Pharma Americas, Inc.0 个研究点目标入组 420 人开始时间: 2010年12月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is =18 years of age.
- •2. Subject has been treated consistently for chronic, non-cancer-related pain with any oral, transdermal, intravenous or subcutaneous opioid (full agonist) other than methadone for at least 30 days prior to screening, and will continue opioid therapy throughout the study.
- •3. Subject must have OBD, which is defined as having an average of <3 spontaneous bowel movements (SBMs) per week during the screening period (with spontaneous” defined as bowel movements [BMs] occurring without the use of laxatives/stool softeners) and at least one of the following for at least 25% of SBMs during each week of the screening period (as reported in the daily diary) :
- •Hard or very hard stools;
- •Sensation of incomplete evacuation; and/or
- •Moderate to very severe straining associated with SBMs.
- •4. If subject has a history of chronic constipation (= 90 days), condition of constipation must have been exacerbated by the initiation of opioid treatment.
- •5. If subject is taking concomitant medication (prescribed or over-the-counter) that affects gastrointestinal motility (other than opioid therapy), he/she must discontinue use from the Screening Visit through the completion of the study; these medications include:
- •Anticholinergics*, anti-spasmodics, cholinesterase inhibitors, anti-diarrhea, anti-constipation, or prokinetic agents;
- •Laxative agents, including homeopathic remedies;
- •Tricyclic antidepressants; and
- •Any medications at the discretion of the Investigator known to relieve or cause constipation, bloating, or other constipation-related symptoms.
- •6. If subject has confirmed diagnosis of clinical depression and he/she has been treated with SSRIs, SNRIs, or MAO inhibitors, treatment must have been at a stable dose for at least 30 days prior to the Screening Visit and not likely to change during the study.
- •7. Subject is willing to discontinue use of laxative and stool softeners from the Screening Visit through the completion of the study (use of approved rescue laxatives will be allowed under certain protocol-specified circumstances).
- •8. If subject is taking a fiber supplement, usage must have been at a stable dose and schedule for at least 30 days prior to the Screening Visit and not likely to change during the study.
- •9. Subject must be willing and able to fill out his/her own electronic diary and can comply with daily data collection.
- •10. Subject daily diary is at least 70% compliant for the screening period.
- •11. Subject is capable of making an informed decision, and has read, understood, and signed the approved Informed Consent Form.
- •*Except ipratropium bromide or any inhaled or nasal-spray forms of this medication.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 388
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 32
排除标准
- •1. Subject is receiving opioid therapy for cancer-related pain, abdominal pain, scleroderma, and/or for the management of drug addiction.
- •2. Subject is receiving methadone, methadone HCl, or a congener of methadone either alone or as part of opioid regimen.
- •3. Subject has current evidence of, or has been treated for, cancer within the past 5 years (with the exception of localized basal cell, squamous cell skin cancer, or in situ cancer that has been resected).
- •4. Subject has adjusted (increased or decreased by +/-30%) dosage (in MEDD) of opioid treatment, has changed
- •opioid agents, or has changed route of opioid administration within 30 days of screening, or is likely to
- •discontinue or adjust dosage by +/-30% over the course of the study.
- •5. Subject has known or suspected anatomic or organic disorders of the large or small bowel; e.g.:
- •Associated with a mechanical bowel obstruction (e.g., tumor, hernia, obstructive polyps), or pseudoobstruction;
- •Associated with large or small bowel disorder such as ulcerative colitis or Crohn’s disease.
- •6. Subject has constipation that, according to the Investigator’s clinical judgment, is not the result of or not
- •exacerbated by opioid use, or is suffering from known or suspected secondary cause of constipation, including but not limited to: dietary disorders (e.g., malnutrition), neurologic disorders (e.g., spinal cord disorders), other congenital disorder, or endocrine disorders (e.g., hypothyroidism or diabetes).
- •7. Subject has impaired renal function identified at the Screening Visit (i.e., serum creatinine concentration > 1.8 mg/dL).
- •8. Subject has experienced an unexplained, clinically significant weight loss defined as > 5% weight loss within 90 days prior to the Screening Visit.
- •9. Subject has undergone a gastrointestinal or abdominal surgical procedure within 90 days prior to the Screening Visit, or has had a bowel resection at any time.
- •10. Subject is non-ambulatory.
- •11. Subject is unable to eat or drink, take oral medications, or to hold down oral medications due to vomiting.
- •12. Female subject of childbearing potential is unable or unwilling to use a protocol-specified method of birth control.
- •13. Female subject of childbearing potential has a positive screening pregnancy test, is currently pregnant or nursing, or plans to become pregnant or nurse during the clinical study.
- •14. According to Investigator’s clinical judgment, subject has clinically significant cardiovascular disease.
- •15. According to Investigator’s clinical judgment, subject has clinically significant, unexplained liver or lung disease, neurologic or psychiatric disorders (excluding depression), or any other systemic disease. If explained, the subject may be enrolled, if in the Investigator’s opinion, the condition would not interfere with safety or efficacy assessments, or result in an increased risk of participation to the subject.
- •16. Subject has a history of alcohol or drug abuse within 180 days prior to Screening Visit.
- •17. Subject demonstrates a potential for non-compliance with the study protocol (i.e., dosing schedule, visit schedule, diary completion, or study procedures).
- •18. Subject has participated in another study with an investigational drug, device, or procedure within the 30 days preceding the Screening Visit.
- •19. Subject has received AMITIZA®, lubiprostone, SPI-0211, or RU-0211 at any time prior to participation in this study.
研究者
相似试验
进行中（未招募）
1 期
A 26 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by LevodopaParkinson's Disease Subjects with Levodopa-Induced DyskinesiasMedDRA version: 17.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-001132-10-ESOsmotica Pharmaceutical Corp.162
进行中（未招募）
不适用
A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study to Evaluate the Efficacy and Safety of CJC-1295 administered for 12 weeks in HIV-Infected Patients with HIV-associated Visceral ObesityPatients 18 to 65 years old with HIV-associated visceral obesity, on a stableantiviral regimen for at least 6 weeks, with a viral load =1,000 copies/mL andCD4 count =200 cells/mm3, a body mass index (BMI) of =24 and =30 kg/m2,a waist-to-hip ratio of =0.95 in men or =0.90 in women, and a waistcircumference of =90 cm in men or =85 cm in women.EUCTR2005-003797-25-DEConjuChem, Inc.150
进行中（未招募）
1 期
Asunercept for the treatment of patients with moderate to severe COVID-19 diseaseModerate to Severe COVID-19 DiseaseMedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862EUCTR2021-006005-30-DEApogenix AG
进行中（未招募）
1 期
Asunercept for the treatment of patients with moderate to severe COVID-19 diseaseEUCTR2021-006005-30-ATApogenix AG640
进行中（未招募）
1 期
A 16 Week Clinical Study to Evaluate the Use of Long-Acting Amantadine to Treat Parkinson's Disease Patients with Abnormal Involuntary Movements caused by LevodopaParkinson's Disease Subjects with Levodopa-Induced DyskinesiasMedDRA version: 17.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-001131-36-ESOsmotica Pharmaceutical Corp.162